Reversal of HOCl-LDL Induced Arrhythmia by Ranolazine Superfusion

Medical University of Graz
Department of Cardiology
Postdoctoral Researcher

Overall

Quality of Results

Ease-of-Optimization

What do these ratings mean?
Write a Review

Company:

Tocris Bioscience

Product Name:

Ranolazine dihydrochloride

Catalog Number:

3118/50

Guinea pig ventricular cardiomyocytes were treated (12–16 hr) with HOCl-LDL (250 µg/ml). Cells were patched and stimulated at a frequency of 1 Hz. Representative action potentials (shown in Image) recorded in the same cell are shown before (A) and after (B) superfusion with Ranolazine (10 µM, 5 min). For comparative purpose representative APs of a control cardiomyocyte are shown (C).

Experimental Design and Results Summary

Application

Cardiac electrophysiology

Starting Material

Primary ventricular cardiomyocytes

Protocol Overview

Guinea pig ventricular cardiomyocytes were treated (12–16 hr) with HOCl-LDL (250 µg/ml). Cells were patched and stimulated at a frequency of 1 Hz followed by superfusion with Ranolazine (10 µM, 5 min).

Tips

N/A

Results Summary

Ranolazine superfusion for 5 min resulted in reversal of arrhythmic events induced by HOCl-LDL in cardiomyocytes.

DOI or PMID #

N/A

Additional Notes

N/A

Related Categories

Image Gallery

Summary

The Good

Works as expected

The Bad

N/A

The Bottom Line

Reversal of HOCl-LDL induced arrhythmia by ranolazine superfusion

Join the discussion